February 15th 2021
By Tony Hagen
Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.
February 12th 2021
The Bengaluru, India, company said the fast-acting biosimilar will improve affordability of insulin in Europe, which also faces rising prices and access problems.
February 11th 2021
Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.
January 27th 2021
The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.
December 24th 2020
The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.
December 14th 2020
The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected to be followed by a European Commission final decision early in 2021.
November 30th 2020
The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach.
November 16th 2020
The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.
November 2nd 2020
By Deana Ferreri, PhD
This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.
October 31st 2020
By Sarfaraz K. Niazi, PhD
The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.
